Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Nd:YAG laser vs topical control Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ axilla · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Nd:YAG laser vs topical control Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ groin · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Adalimumab weekly vs placebo Frequency of treatment discontinuation · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | RR 5 [0.25, 101.63] | 1 study · 102 participants | Moderate |
Niosomal methylene blue gel PDT vs free methylene blue gel PDT HS‐LASI score · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | no estimate extracted | 1 study · 20 participants | Low |
Staphage lysate vs placebo broth Physician global assessment · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | RR 6.25 [1.68, 23.27] | 1 study · 27 participants | Moderate |
Adalimumab weekly vs placebo Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | RR 0.94 [0.55, 1.62] | 1 study · 102 participants | Moderate |
Adalimumab weekly vs placebo Proportion with improvement in pain VAS · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | RR 1.77 [1.02, 3.07] | 1 study · 96 participants | Moderate |
Adalimumab weekly vs placebo Change in modified Sartorius scale score (imputation) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | no estimate extracted | 1 study · 102 participants | Moderate |
Adalimumab every other week vs placebo Change in DLQI score (LOCF) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | no estimate extracted | 2 studies · 124 participants | High |
Adalimumab every other week vs placebo Frequency of serious adverse effects · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane | RR 1.47 [0.26, 8.44] | 2 studies · 124 participants | High |
Oral aciclovir (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ aciclovir 800 mg twice daily · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.08 [0.62, 1.87] | 1 study · 237 participants | Moderate |
Oral aciclovir (long‐term) vs placebo Rate of adherence to the regimen of the preventative intervention · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Valaciclovir (short‐term) vs placebo Incidence of HSL during use of the preventative intervention (by clinical evaluation) · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.55 [0.23, 1.28] | 1 study · 125 participants | Moderate |
Valaciclovir (short‐term) vs placebo Incidence of HSL during use of the preventative intervention (by culture) · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.47 [0.21, 1.08] | 1 study · 125 participants | Moderate |
Valaciclovir (short‐term) vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.33 [0.71, 2.5] | 1 study · 125 participants | Moderate |
Valaciclovir (short‐term) vs placebo Viral load (shedding) in saliva · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.16 [0.02, 1.26] | 1 study · 120 participants | Moderate |
Valaciclovir (long‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 95 participants | Moderate |
Valaciclovir (long‐term) vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.86 [0.51, 1.46] | 1 study · 95 participants | Moderate |
Valaciclovir (suppressive regimen vs episodic regimen) Incidence of herpes labialis during use of the preventative intervention (number of recurrences per participant per month) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 120 participants | Very low |
Valaciclovir (suppressive regimen vs episodic regimen) Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.21 [0.78, 1.87] | 1 study · 152 participants | Very low |
Valaciclovir (suppressive regimen vs episodic regimen) Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 120 participants | Very low |
Oral aciclovir (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ aciclovir 400 mg twice daily · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.26 [0.13, 0.51] | 2 studies · 177 participants | Low |
Valaciclovir (suppressive regimen vs episodic regimen) Severity (pain) of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 120 participants | Very low |
Valaciclovir (suppressive regimen vs episodic regimen) Severity (maximum total lesion area) of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 120 participants | Very low |
Famciclovir vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ famciclovir 125 mg · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.74 [0.5, 1.11] | 1 study · 120 participants | Moderate |
Famciclovir vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ famciclovir 250 mg · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.69 [0.45, 1.04] | 1 study · 122 participants | Moderate |
Famciclovir vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ famciclovir 500 mg · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.82 [0.56, 1.21] | 1 study · 121 participants | Moderate |
Famciclovir vs placebo Duration of attack of recurrent herpes labialis during use of the preventative intervention ‐ famciclovir 125 mg · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | HR 1.63 [0.84, 3.15] | 1 study · 47 participants | Moderate |
Famciclovir vs placebo Duration of attack of recurrent herpes labialis during use of the preventative intervention ‐ famciclovir 250 mg · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | HR 1.59 [0.79, 3.2] | 1 study · 45 participants | Moderate |
Famciclovir vs placebo Duration of attack of recurrent herpes labialis during use of the preventative intervention ‐ famciclovir 500 mg · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | HR 2.39 [1.23, 4.63] | 1 study · 51 participants | Moderate |
Levamisole vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 72 participants | Very low |
Levamisole vs placebo Adverse effects during use of the preventative intervention (leading to withdrawal) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 99 participants | Very low |
Oral aciclovir (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ aciclovir 200 mg 5 times/day · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.46 [0.2, 1.07] | 1 study · 66 participants | Low |
Levamisole vs placebo Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 72 participants | Very low |
Lysine vs placebo Incidence of herpes labialis during use of the preventative intervention (number of recurrences per participant per month) · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Topical aciclovir (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.91 [0.48, 1.72] | 2 studies · 271 participants | Moderate |
Topical aciclovir (short‐term) vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.17 [0.59, 2.32] | 1 study · 191 participants | Low |
Topical aciclovir (short‐term) vs placebo Severity (aborted lesions) of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.02 [0.19, 5.57] | 1 study · 52 participants | Low |
Topical aciclovir (short‐term) vs placebo Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.35 [0.13, 0.94] | 1 study · 181 participants | Low |
Topical aciclovir and 348U87 cream (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by culture) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.78 [0.19, 3.14] | 1 study · 51 participants | Very low |
Topical aciclovir and 348U87 cream (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.46 [0.53, 3.99] | 1 study · 51 participants | Very low |
Topical aciclovir and 348U87 cream (short‐term) vs placebo Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Topical aciclovir and 348U87 cream (short‐term) vs placebo Severity of attack of recurrent herpes labialis during use of the preventative intervention (maximum lesion area) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Oral aciclovir (short‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by culture) ‐ aciclovir 400 mg twice daily · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 0.05 [0, 0.7] | 1 study · 30 participants | Low |
Topical foscarnet vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 1.08 [0.82, 1.4] | 1 study · 295 participants | Moderate |
Topical foscarnet vs placebo Adverse effects during use of the preventative intervention (leading to discontinuation) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 2.96 [0.12, 72.11] | 1 study · 302 participants | Moderate |
Topical foscarnet vs placebo Adverse effects during use of the preventative intervention (application site reactions) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | RR 2.47 [0.79, 7.69] | 1 study · 302 participants | Moderate |
Topical foscarnet vs placebo Duration of attack of recurrent herpes labialis during use of the preventative intervention (healing time) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 125 participants | Moderate |
Topical foscarnet vs placebo Severity of attack of recurrent herpes labialis during use of the preventative intervention (mean lesion area) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 124 participants | Moderate |
Topical foscarnet vs placebo Severity of attack of recurrent herpes labialis during use of the preventative intervention (maximum lesion area) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane | no estimate extracted | 1 study · 124 participants | Moderate |